en · de · es · fr · pt
bench-notes.peptides6088.com › Wiki › Background And Development History — Quick Reference

Background And Development History — Quick Reference

By Editorial Desk · published 2026-04-07 · last reviewed 2026-04-22 · Wiki

Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Identity And Research Background

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

Related pages on this site

Mechanism And Metabolic Effects

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Reference notes

=== Psychological === At normal therapeutic doses, the most common psychological side effects of amphetamine include increased alertness, apprehension, concentration, initiative, self-confidence and sociability, mood swings (elated mood followed by mildly depressed mood), insomnia or wakefulness, and decreased sense of fatigue. Less common side effects include anxiety, change in libido, grandiosity, irritability, repetitive or obsessive behaviors, and restlessness; these effects depend on the user's personality and current mental state. Amphetamine psychosis (e.g., delusions and paranoia) can occur in heavy users. Although very rare, this psychosis can also occur at therapeutic doses during long-term therapy. According to the FDA, "there is no systematic evidence" that stimulants produce aggressive behavior or hostility. Amphetamine has also been shown to produce a conditioned place preference in humans taking therapeutic doses, meaning that individuals acquire a preference for spending time in places where they have previously used amphetamine.

The FGF-2 internal ribosome entry site is an RNA element present in the 5' UTR of the mRNA of fibroblast growth factor-2. It has been found that the FGF-2 internal ribosome entry site (IRES) activity is strictly controlled and highly tissue specific. It is thought that translational IRES dependent activation of FGF-2 plays a vital role in embryogenesis and in the adult brain [1]. When expressed the fibroblast growth factor 2 FGF-2 protein plays a pivotal role in cell proliferation, differentiation and survival as well as being involved in wound-healing [1,2].

An initial tree, Ti, is randomly selected. A neighbour tree, Tj, is selected from the collection of trees. The ratio, R, of the probabilities (or probability density functions) of Tj and Ti is computed as follows: R = f(Tj)/f(Ti) If R ≥ 1, Tj is accepted as the current tree. If R < 1, Tj is accepted as the current tree with probability R, otherwise Ti is kept. At this point the process is repeated from Step 2 N times. The algorithm keeps running until it reaches an equilibrium distribution. It also assumes that the probability of proposing a new tree Tj when we are at the old tree state Ti, is the same probability of proposing Ti when we are at Tj. When this is not the case Hastings corrections are applied. The aim of Metropolis-Hastings algorithm is to produce a collection of states with a determined distribution until the Markov process reaches a stationary distribution. The algorithm has two components:

Sources: en.wikipedia.org

Reference notes

In 1996, the World Health Organization (WHO) launched the EMF (ElectroMagnetic Fields) Project to bring together current knowledge and available resources from key international and national organizations and scientific institutions on electromagnetic fields. The German Federal Office for Radiation Protection (BfS) published the following recommendation in 2006:

Parmotrema perlatum is used as a spice, particularly in the cuisine of Tamil Nadu. It is especially prevalent in Chettinad cuisine, being used in the popular rice dish biryani, and also in many meat and vegetarian dishes. In its raw state, black stone flower does not have much taste or fragrance. However, when put in contact with heat, especially hot cooking oil or ghee, it releases a distinctive earthy, smoky flavour and aroma. This property of black stone flower is especially valued in the tempering step of cooking a number of Indian dishes. The spice is also integral to various regional masalas throughout the Indian subcontinent. Parmotrema perlatum is a key ingredient in masalas such as Kala and Goda masala of Maharashtra, Anglo-Indian bottle masala, bhojwar masala from Hyderabad, and potli masala in Lucknow. It is what many cooks and commercial spice blend makers believe sets apart accomplished dishes from those made by amateurs. Despite its lack of a specific aroma or describable flavour in its raw form, its contribution to the complex flavour profile of these spice blends is highly valued.

Cape Town ⟷ Kimberley ⟷ Johannesburg: General freight Durban ⟷ Richards Bay: Coastal freight Johannesburg ⟷ Durban: General freight (SA's busiest intermodal freight corridor) Johannesburg ⟷ Gqeberha / Ngqura: Automotive exports and manufactured goods Johannesburg ⟷ Polokwane: Mining supplies, and agricultural and manufacturing freight Johannesburg ⟷ Richards Bay: General freight Johannesburg ⟷ KuGompo City: Automotive and general freight Johannesburg ⟷ Komatipoort: Cross-border freight to Mozambique and the rest of the SADC Johannesburg ⟷ Beitbridge: Cross-border freight into Zimbabwe Johannesburg ⟷ Mahikeng / Ramatlabama: Cross-border freight into Botswana As of 2026, Transnet Freight Rail moves 17% of South Africa's freight annually, including 100% of its export coal and iron ore. The company coordinates its rail freight services with other Transnet divisions, such as ports, pipelines, and engineering. With over 25,000 employees, Transnet Freight Rail generates over R14 billion in annual revenue. For its 2025/2026 financial year, Transnet expected to transport a total rail cargo volume of around 168 million tons, up around 5%, from 160.1 million tons the year before. Under the South African Government's rail restructuring plan, the goal is for Transnet to reach a transport capacity of 185 million tons, with a further 65 million tons transported by private operators, by 2030. This would make for a total South African cargo rail capacity of 250 million tons per year.

Growth of many unfavorable wild yeasts is generally slowed at lower cellar temperatures, so many winemakers who wish to inhibit the activities of these yeasts before the more favorable Saccharomyces yeast kick in, will often chill their must, such as the practice of "cold soaking" the must during a pre-fermentation maceration at temperatures between 4–15 °C (39–59 °F). Though some species, such as Brettanomyces, will not be inhibited and may even thrive during an extended period of cold soaking.

Sources: en.wikipedia.org

Notes from published material

ribonucleotide A nucleotide containing ribose as its pentose sugar component, and the monomeric subunit of ribonucleic acid (RNA) molecules. Ribonucleotides canonically incorporate any of four nitrogenous bases: adenine (A), guanine (G), cytosine (C), and uracil (U). Compare deoxyribonucleotide.

Recently, several studies have highlighted the prospect of using carbon nanotubes as building blocks to fabricate three-dimensional macroscopic (>100 nm in all three dimensions) all-carbon devices. Lalwani et al. have reported a novel radical-initiated thermal crosslinking method to fabricate macroscopic, free-standing, porous, all-carbon scaffolds using single- and multi-walled carbon nanotubes as building blocks. These scaffolds possess macro-, micro-, and nano-structured pores, and the porosity can be tailored for specific applications. These 3D all-carbon scaffolds/architectures may be used for the fabrication of the next generation of energy storage, supercapacitors, field emission transistors, high-performance catalysis, photovoltaics, and biomedical devices, implants, and sensors.

=== Birds === Close to ninety percent of known avian species are monogamous, compared to five percent of known mammalian species. The majority of monogamous avians form long-term pair bonds which typically result in seasonal mating: these species breed with a single partner, raise their young, and then pair up with a new mate to repeat the cycle during the next season. Some avians such as swans, bald eagles, California condors, and the Atlantic Puffin are not only monogamous, but also form lifelong pair bonds. When discussing the social life of the bank swallow, Lipton and Barash state:

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network